Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Propanc Biopharma, Inc. PPCBD OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
28/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Propanc Biopharma, Inc. (PPCBD) is a Biotechnology company in the Healthcare sector, currently trading at $5.68. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $59M (loss), growing at -1034.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $14M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 1.5 (strong liquidity). Debt-to-assets is 8.8%. Total assets: $20M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

PPCBD SharesGrow Score Overview

37/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PPCBD

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
PPCBD: +0%/yr revenue is, -1034.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PPCBD: Debt-to-Equity (D/E) ratio 0.12 (conservative), Current ratio is 1.5 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
PPCBD: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.5-221.55688
Volume139
Avg Volume (30D)532
Market Cap$87.31K
Beta (1Y)1.20
Share Statistics
EPS (TTM)-332.55
IPO Date2012-11-12
Employees1
CEOJames Nathanielsz
Financial Highlights & Ratios
EBITDA$-58.34M
Net Income$-58.92M
Operating Income$-57.28M
Total Cash$12.09K
Total Debt$1.73M
Net Debt$1.71M
Total Assets$19.63M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryAU
ExchangeOther OTC
CurrencyUSD

Price Chart

Track all markets on TradingView
PPCBD
Propanc Biopharma, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
1.50 52WK RANGE 221.56

People Also View

BRTX
BRTX
BioRestorative Therapies, Inc.
$0.25
-2.37%
 PJET
PJET
Priority Aviation, Inc.
$0.00
+0.00%
 NOUV
NOUV
Nouveau Life Pharmaceuticals, Inc.
$0.00
+0.00%
 KALY
KALY
Kali, Inc.
$0.00
+0.00%
 ENDV
ENDV
Endonovo Therapeutics, Inc.
$0.00
0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message